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Abstract
Background: The management of anticoagulation for cancer- associated thrombosis 
(CAT) in patients with thrombocytopenia is controversial. Whereas some studies 
suggest that administration of reduced- dose low- molecular- weight heparin (LMWH) 
or temporary discontinuation for moderate and severe thrombocytopenia may be a 
safe and effective, others suggest full- dose anticoagulation with transfusion support. 
We sought to address this important knowledge gap and summarize the literature 
comparing these two common management strategies.
Methods: A systematic review of the literature (PROSPERO CRD42017077127) 
using MEDLINE (inception to September 2017) was conducted. We included studies 
that reported recurrent venous thromboembolism (VTE) and major bleeding compli-
cations among patients treated with both of the two most common management 
strategies: therapeutic anticoagulation with platelet transfusion support and dose- 
modified anticoagulation for periods when the platelet count is <50 × 109/L.
Results: A total of 134 article records were identified on the initial search and 10 
articles underwent full text review. Two observational studies met the inclusions cri-
teria. A total of 121 patients with CAT and thrombocytopenia were included. Forty- 
two of these patients had pulmonary embolism and 87 had deep vein thrombosis 
(DVT) including 38 upper extremity DVT. Overall, 27% of patients, regardless of their 
treatment strategy, experienced recurrent VTE. Thirteen percent of anticoagulated 
patients (15% of all patients) experienced a major bleeding episode. Meta- analysis 
could not be conducted.
Conclusions: Our findings do not support one management strategy over another to 
treat CAT patients with thrombocytopenia. However, the data highlights the height-
ened risk of recurrent VTE in this patient population despite the thrombocytopenia.
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1  | INTRODUCTION
Venous thromboembolism (VTE) affects between 1% and 8% of 
all patients undergoing cancer therapy and is the second leading 
cause of death among outpatients undergoing chemotherapy.1,2 
Management of cancer- associated thrombosis (CAT) requires spe-
cial considerations and is different from the management of VTE in 
non- cancer patients.3 It is made more challenging by the presence 
of other complications of cancer therapy, such as thrombocytope-
nia, which is common among patients undergoing chemotherapy for 
hematologic malignancy and certain solid tumors. While thrombo-
cytopenia has not shown any protective benefits against recurrent 
VTE among CAT patients, it has been associated with increased rates 
of bleeding.4 Therefore, the management of anticoagulation in this 
patient population requires special attention.
Low- molecular- weight heparin (LMWH) is known to reduce the 
risk of VTE recurrence and is currently recommended by all clinical 
practice guidelines for the initial treatment of CAT.5 However, its 
optimal dosing for the management of CAT in patients with throm-
bocytopenia is unknown. Whereas some studies suggest that admin-
istration of reduced- dose LMWH for moderate thrombocytopenia 
(platelet counts <50 × 109/L) and temporary discontinuation for se-
vere thrombocytopenia (platelet counts <25 × 109/L) may be a safe 
and effective, others suggest full- dose anticoagulation with trans-
fusion support in thrombocytopenia.6,7 We sought to address this 
important knowledge gap and summarize the literature comparing 
these two common management strategies for the management of 
anticoagulation in the setting of CAT and thrombocytopenia: full dose 
anticoagulation with platelet support and dose- modified LMWH.
2  | METHODS
This systematic review was registered on PROSPERO (registra-
tion number CRD42017077127). We searched Medline (inception 
to September 2017) for relevant articles. Search terms included 
(“neoplasms”[MeSH Terms] AND “thrombocytopenia”[MeSH 
Terms]) AND “anticoagulants”[MeSH Terms]). Articles were included 
if they reported outcomes for patients treated for CAT during peri-
ods of treatment- related thrombocytopenia. Articles were excluded 
if they did not report recurrent VTE and bleeding outcomes sepa-
rately for patients treated with both a dose- modified strategy and 
a full- dose strategy with transfusion support or were case reports/
series including ≤5 patients.
The primary efficacy and safety measures was recurrent VTE and 
major bleeding episodes, respectively. Recurrent VTE was defined 
as symptomatic, imaging- confirmed progression of index thrombo-
sis or thrombosis at a new site. Major bleeding episode was defined 
as per the International Society of Thrombosis and Haemostasis 
definition.8
Quality assessments of the observational studies were carried 
out using the ROBINS- 1 tool from the Cochrane Method group 
(Supplementary Appendix S1).9
3  | RESULTS AND DISCUSSION
A total of 134 article records were identified on the initial search and 
10 articles underwent full text review. Of these, six were excluded 
for failing to include patients undergoing management according to 
both treatment strategies,6,10-14 one was excluded for failure to re-
port outcomes of both strategies7 and one was excluded for study 
design (case series of only five patients).15 The remaining two stud-
ies were included and are described below. Ten studies which were 
excluded due to only utilizing one treatment strategy are outlined in 
Table 1 for comparison.12,15–20
Overall, 121 patients with CAT and thrombocytopenia were 
included in our review (Table 2). Forty- two of these patients had 
pulmonary embolism (PE) and 87 had deep vein thrombosis (DVT) 
including 38 upper extremity DVT (several patients had multiple 
events at different locations).
The first study was a retrospective cohort study of 74 pa-
tients with CAT and thrombocytopenia defined as a platelet count 
<100 × 109/L.23 Patients were categorized according to three dif-
ferent management groups: no antithrombotic therapy, complete 
course of antithrombotic therapy consisting of therapeutic dose 
anticoagulation given daily for ≥3 months, or partial antithrombotic 
therapy indicating a course of anticoagulation with reduced dose in-
tensity, duration, or continuity. Patients receiving full- dose antico-
agulation had a higher median platelet count at the time of the VTE 
event and at nadir, had a shorter duration of thrombocytopenia, were 
more likely to have a PE or lower extremity DVT (and less likely to 
have upper extremity DVT) and were less likely to receive platelet 
transfusions. Seventeen subjects received no anticoagulation, 27 
received partial antithrombotic therapy, and 30 patients received a 
complete course of antithrombotic therapy. A total of 23 recurrent 
VTE events and 13 major bleeding episodes were reported (Table 2). 
The majority of recurrent VTE events occurred in patients receiving 
Essentials
• The management of anticoagulation in patients with thrombocytopenia is controversial.
• Some studies suggest to administer reduced-dose low-molecular-weight heparin (LMWH).
• While other studies suggest full-dose anticoagulation using LMWH and transfusion support.
• The results from our systematic review do not support one management strategy over another.
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no anticoagulation, followed by patients receiving prophylactic or 
intermediate doses of anticoagulation (partial anticoagulation). The 
majority of major bleeding episodes were reported in patients re-
ceiving partial anticoagulation, followed by patients receiving no 
anticoagulation. Univariate logistic regression models reported an 
increased risk of recurrent VTE for patients with hematologic malig-
nancy (OR 11.0; 95% CI: 1.36- 88.66), thrombocytopenia lasting lon-
ger than 1 month (OR 4.67; 95% CI: 1.23- 17.74) and patients with an 
index upper extremity DVT (OR 4.10; 95% CI: 1.45- 11.63). The risk 
of recurrent VTE seemed lower among patients receiving full ther-
apeutic doses of LMWH (OR 0.13; 95% CI: 0.03- 0.58) as well as for 
those with index PE (OR 0.17; 95% CI: 0.04- 0.64). The risk of major 
bleeding episodes seem higher among patients with a prior history of 
hemorrhage (OR 6.33; 95% CI: 1.34- 29.96) in this patient population.
The second identified study was a retrospective cohort study 
including 47 patients with CAT and thrombocytopenia (platelets 
<50 x109/L) and 81 patients without thrombocytopenia.25 Among 
the thrombocytopenic patients, 14 received therapeutic anti-
coagulation with LMWH and 22 received dose- modified LMWH 
(enoxaparin 40 mg daily during the period of significant thrombo-
cytopenia). Median follow- up was 24.6 months in thrombocyto-
penic patients. Differences between subjects receiving different 
treatments within the thrombocytopenic group were not reported. 
Eleven and 5 patients had a recurrent VTE and major bleeding epi-
sode, respectively (Table 2). Four of the five major bleeding events 
occurred in patients receiving therapeutic anticoagulation. Two of 
the 11 recurrent VTE events occurred in patients receiving thera-
peutic anticoagulation.
A quality assessment of each study was performed using the 
ROBINS- 1 method.25 Both studies were judged to be at serious risk 
of bias in two domains (confounding and selection of reported re-
sults) but not at critical risk of bias in any domain.
TABLE  1 Outcomes of anticoagulation strategies in thrombocytopenic hematologic malignancy patients
Author (year) Design Treatment strategies (n) Recurrence Bleeding events
Duration of 
follow- up
Khanal (2016)21a Retrospective cohort Therapeutic LMWH or VKA 
(15)
5 4 24.6 months
Prophylactic/reduced 
LMWH (22)
3 1
Campbell (2017)7 Case series Therapeutic LMWH or UFH 
(13)
1 1 6 months
Li (2017)18 Retrospective cohort LMWH/UFH (132) 2 20 359 days
No anticoagulation (72) 1 10
Houghton (2017)17 Retrospective cohort Anticoagulation (45) 1 12 100 days
No anticoagulation (33) 5 1
Drakos (1992)16 Case series Prophylactic/reduced 
LMWH (5)
0 0 NR
Lim (2016)15 Case series Therapeutic LMWH (1) 0 0 NR
Prophylactic/reduced 
LMWH (3)
0 2
No anticoagulation (1) 0 0
Oliver (2015)22 Retrospective cohort Therapeutic LMWH (13) 0 5 6 months
Prophylactic/reduced 
LMWH (8)
0
No anticoagulation (14) 0 1
Imberti (2004)12 Case series Therapeutic LMWHb 0 0 NR
Ibrahim (2005)9 Case series Prophylactic/reduced 
LMWH (26)
NR 6 NR
Schimmer (1998)20 Retrospective cohort Therapeutic UFH (10) NR 3 NR
Kopolovic (2015)23 Retrospective cohort Full anticoagulation (30) 8 2 3 months
Partial anticoagulation (27) 12 9
No anticoagulation (17) 3 2
Samuelson (2017)24 Retrospective cohort Therapeutic LMWH or UFH 
(82)
5 33 30 days
LMWH, low- molecular- weight heparin; UFH, unfractionated heparin; VKA, vitamin-K antagonist.
aStudy included patients with platelets >50, only those with platelets <50 included here.
bLMWH was dose reduced for platelets <20.
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The optimal management of CAT with anticoagulation in throm-
bocytopenic patients is an important and frequent challenge fac-
ing clinicians. Our systematic review was only able to identify two 
observational studies reporting recurrent VTE and major bleeding 
complications among patients treated with both of the two most 
common management strategies: therapeutic anticoagulation with 
platelet transfusion support and dose- modified anticoagulation for 
periods when the platelet count is <50 × 109/L.
Both studies reported high risk of recurrent VTE despite 
thrombocytopenia. Overall, 27% of patients, regardless of their 
treatment strategy, experienced recurrent VTE. This is strik-
ing even in the context of the known higher rates of recurrent 
VTE commonly seen in patients with CAT. For example, in the 
CLOT trial, a rate of recurrence of 17% in the oral anticoagu-
lant arm was considered to be unacceptably high in comparison 
to a rate of 9% among patients treated LMWH.3 This adds to a 
growing body of literature supporting the fact that thrombocy-
topenia, while accompanied by an increased rate of bleeding in 
cancer patients, is not accompanied by a decreased rate of VTE 
complications.24,26,27
The rate of major bleeding episodes, on the other hand, was 
more modest and nearly half the reported rate of recurrent VTE. 
Thirteen percent of anticoagulated patients (15% of all patients) ex-
perienced a major bleeding episode. This rate is consistent with a 
previously published study among patients with treatment- related 
thrombocytopenia not receiving anticoagulation.4
The best anticoagulation strategy (full- dose anticoagulation 
with platelet support or dose- modified LMWH) to use in patients 
with CAT and thrombocytopenia remains unclear. The results of the 
study by Kopolovic and colleagues support the concept that con-
tinuous, therapeutic anticoagulation offers a lower risk of recurrent 
VTE with a similar rate of bleeding complication, whereas the by 
Khanal and colleagues suggest that a dose- modified strategy might 
result in both lower rates of VTE and major bleeding complications. 
The findings were similarly mixed in studies excluded from this 
review for investigating only one of the two strategies. Both VTE 
recurrence and bleeding rates were high, particularly in the acute 
period, and were seen across treatment strategies, including holding 
of anticoagulation. No study identified a distinct platelet threshold 
below which a modified strategy (either transfusion support or dose 
reduction) improved outcomes.
Both included studies had numerous limitations that are import-
ant to highlight. The studies were retrospective, nonrandomized, 
and subject to high rates of bias. It is also unclear if the target platelet 
threshold was maintained in patients with thrombocytopenia receiv-
ing full- dose anticoagulation. Decisions regarding which strategy 
to use were likely dependent on multiple factors, including patient 
characteristics not addressed in this study and provider experience 
and judgment. Patients whose clinical characteristics suggested they 
were at high risk of recurrent VTE were likely preferentially given full 
dose anticoagulation and patients thought to be at either low risk 
of recurrence or high risk of bleeding likely received reduced dose 
or no anticoagulation. Ultimately prospective, randomized trials are T
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desperately needed to adequately compare these two anticoagula-
tion management strategies and provide guidance to clinicians.
Our review has a number of limitations, the most important one 
is the small number of included studies and lack of any randomized, 
controlled trials. Additionally there was a large degree of hetero-
geneity between studies, including population (thrombocytopenia 
defined differently), intervention (dosing) length of follow- up and 
definition of outcomes. This, in addition to the small sample size, 
prohibited pooling of data.
In conclusion, our findings do not support one management 
strategy over another to treat CAT patients with thrombocytopenia. 
However, the data highlights the heightened risk of recurrent VTE 
in this patient population despite the thrombocytopenia. Therefore, 
clinicians should consider initiating anticoagulation (therapeutic or 
reduced- dose LMWH) in the absence of absolute contraindications 
for these patients.
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